Nintedanib for the treatment of refractory progressive rheumatoid arthritis-related interstitial lung disease: a real-life case series

Rheumatology (Oxford). 2020 Dec 1;59(12):3983-3986. doi: 10.1093/rheumatology/keaa503.

Authors

Javier Narváez¹, Vanesa Vicens-Zygmunt², Juan-José Alegre³, Silvia Herrera-Lara⁴, Joan-Miquel Nolla¹, Maria Molina-Molina²

Affiliations

¹ Department of Rheumatology, Hospital Universitario de Bellvitge.
² Department of Pneumology (Unit of Interstitial Lung Diseases), Hospital Universitario de Bellvitge, Barcelona.
³ Department of Rheumatology and.
⁴ Department of Pneumology, Hospital Universitario Dr. Peset, Valencia, Spain.

PMID: 32940704
DOI: 10.1093/rheumatology/keaa503

No abstract available

Publication types

Letter

MeSH terms

Aged
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / complications*
Female
Humans
Indoles / therapeutic use*
Lung Diseases, Interstitial / drug therapy*
Lung Diseases, Interstitial / etiology
Male
Middle Aged

Substances

Antirheumatic Agents
Indoles
nintedanib